Janux Therapeutics (NASDAQ:JANX) Insider Sells $32,965.73 in Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) insider Charles Winter sold 2,401 shares of the business’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $13.73, for a total transaction of $32,965.73. Following the sale, the insider directly owned 77,721 shares of the company’s stock, valued at $1,067,109.33. This represents a 3.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Janux Therapeutics Stock Performance

Shares of JANX traded down $0.15 during trading hours on Friday, hitting $13.65. The stock had a trading volume of 1,533,974 shares, compared to its average volume of 2,182,684. Janux Therapeutics, Inc. has a 12-month low of $13.52 and a 12-month high of $61.59. The firm has a market cap of $821.05 million, a P/E ratio of -8.13 and a beta of 2.88. The company’s fifty day simple moving average is $22.51 and its 200 day simple moving average is $23.74.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.21. The firm had revenue of $10.00 million for the quarter, compared to analyst estimates of $3.07 million. As a group, sell-side analysts predict that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Institutional Trading of Janux Therapeutics

Several large investors have recently modified their holdings of the business. Walleye Capital LLC purchased a new stake in shares of Janux Therapeutics during the first quarter worth about $307,000. MetLife Investment Management LLC grew its stake in Janux Therapeutics by 7.9% during the 1st quarter. MetLife Investment Management LLC now owns 18,663 shares of the company’s stock valued at $504,000 after purchasing an additional 1,365 shares in the last quarter. Corebridge Financial Inc. grew its stake in Janux Therapeutics by 11.2% during the 1st quarter. Corebridge Financial Inc. now owns 15,495 shares of the company’s stock valued at $418,000 after purchasing an additional 1,555 shares in the last quarter. Cubist Systematic Strategies LLC increased its holdings in Janux Therapeutics by 88.0% during the 1st quarter. Cubist Systematic Strategies LLC now owns 75,860 shares of the company’s stock worth $2,048,000 after purchasing an additional 35,511 shares during the last quarter. Finally, Alyeska Investment Group L.P. raised its position in shares of Janux Therapeutics by 18.5% in the 1st quarter. Alyeska Investment Group L.P. now owns 408,678 shares of the company’s stock valued at $11,034,000 after purchasing an additional 63,762 shares in the last quarter. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Cantor Fitzgerald reduced their price target on shares of Janux Therapeutics from $200.00 to $150.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 2nd. Wedbush reissued an “outperform” rating and issued a $45.00 target price (down previously from $76.00) on shares of Janux Therapeutics in a research note on Tuesday, December 2nd. Bank of America decreased their price target on shares of Janux Therapeutics from $58.00 to $49.00 and set a “buy” rating for the company in a research report on Tuesday, December 2nd. HC Wainwright lowered their price target on Janux Therapeutics from $70.00 to $45.00 and set a “buy” rating for the company in a report on Tuesday, December 2nd. Finally, Stifel Nicolaus reduced their price objective on Janux Therapeutics from $46.00 to $38.00 and set a “buy” rating on the stock in a research note on Tuesday, December 2nd. Twelve equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Janux Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $61.08.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.